Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy

Autor: Vitaly I. Loginov, M B Stenina, Yu A Nosova, M A Kapralova, G T Sukhikh, S V Khokhlova, A S Tyulyandina, P K Brenner, T. M. Zavarykina, A M Burdennyi, D. S. Khodyrev, G N Khabas, A V Asaturova, M. V. Atkarskaya
Rok vydání: 2020
Předmět:
Adult
Cyclin-Dependent Kinase Inhibitor p21
0301 basic medicine
Genotype
Paclitaxel
medicine.medical_treatment
Carcinoma
Ovarian Epithelial
Polymorphism
Single Nucleotide
General Biochemistry
Genetics and Molecular Biology
Carboplatin
03 medical and health sciences
0302 clinical medicine
Gene Frequency
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Progression-free survival
Allele
Gene
Alleles
Aged
Ovarian Neoplasms
Chemotherapy
business.industry
Proto-Oncogene Proteins c-mdm2
General Medicine
Middle Aged
CDKN1A Gene
medicine.disease
Progression-Free Survival
Gene Expression Regulation
Neoplastic
Treatment Outcome
030104 developmental biology
Genetic marker
Cancer research
Female
Tumor Suppressor Protein p53
Ovarian cancer
business
Polymorphism
Restriction Fragment Length
030217 neurology & neurosurgery
Zdroj: Bulletin of Experimental Biology and Medicine. 169:486-490
ISSN: 1573-8221
0007-4888
DOI: 10.1007/s10517-020-04915-5
Popis: We studied the association of polymorphic markers of cell cycle control genes (Arg72Pro of the TP53 gene, T(-410)G of the MDM2 gene, and Ser31Arg of the CDKN1A gene) in ovarian cancer and progression-free survival following platinum-based chemotherapy. Tumor tissue samples obtained from 49 patients who had undergone chemotherapy were examined. Patients received standard platinum-based chemotherapy and were observed until disease progression. Polymorphic markers of genes were evaluated by PCR-RFLP and real-time PCR. In patients carrying the G allele of the T(-410)G marker of the MDM2 gene, a decreasing trend was observed in median progression-free survival. An increase in the median progression-free survival was observed in carriers of the Pro allele of the TP53 gene (p=0.045). Furthermore, a stronger association was noted with carriers of the minor Pro/Pro homozygous genotype relative to the Arg/Arg genotype (p=0.007). In the subgroup of patients who underwent optimal or complete cytoreductive surgery, carriage of the minor Arg allele of the Ser31Arg marker (CDN1A gene) was associated with a decrease in the median progression-free survival time (p=0.004).
Databáze: OpenAIRE
Externí odkaz: